ProQR Therapeutics N.V. (PRQR)
NASDAQ: PRQR · Real-Time Price · USD
1.720
-0.070 (-3.91%)
At close: Jul 24, 2026, 4:00 PM EDT
1.800
+0.080 (4.65%)
After-hours: Jul 24, 2026, 7:50 PM EDT

ProQR Therapeutics Financials Overview

Millions EUR. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
13.6416.3519.559.534.362.38
Revenue Growth
-30.50%-16.36%105.20%118.51%83.30%-74.84%
Gross Profit
13.6416.3519.559.534.362.38
Operating Income
-46.28-43.45-30.47-31.86-65.16-57.21
Net Income
-45.49-42.18-27.76-28.12-64.42-60.74
Earnings Per Share
-0.43-0.40-0.32-0.35-0.90-0.95
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
81.0992.41149.41118.9394.78187.52
Total Debt
15.7315.9617.2219.7321.9760.37
Net Cash (Debt)
65.3676.45132.1999.1972.8127.15
Net Cash Growth
-43.45%-42.17%33.27%36.24%-42.74%205.94%
Net Cash Per Share
0.620.731.541.221.021.98

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-48.14-52.79-36.3921.55-68.51-26.01
Capital Expenditures
-0.96-1.02-1.42-1.37-0.71-0.48
Free Cash Flow
-49.1-53.81-37.8120.18-69.22-26.5
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
100.00%100.00%100.00%100.00%100.00%100.00%
Operating Margin
-339.31%-265.77%-155.91%-334.48%-1494.82%-2405.80%
Pretax Margin
-333.37%-257.94%-143.05%-292.00%-1470.70%-2551.81%
Profit Margin
-333.51%-258.05%-142.05%-291.18%-1472.91%-2556.73%
FCF Margin
-359.98%-329.18%-193.46%211.83%-1587.89%-1114.21%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJul '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
P/FCF Ratio
---7.19--
PS Ratio
15.4411.0913.7315.2263.96211.05